drugset / Trial / NCT02111070

Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects

NCT02111070 ↗

Phase 1 Completed 44 enrolled Il-Yang Pharm. Co., Ltd.
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Vial INJ.) administered as a single intramuscular injection

Timeline

Start
2012-09
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject IL-YANG FLU Vaccine Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.